The popularity of Viagra initially drove a period of growth for pharma, however recent changes present a complicated picture for those considering a stake. Off-patent competitors are reducing revenue, and ongoing patent challenges add further difficulty to the situation. While specific companies might still gain from adjacent products, the overa… Read More